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Commentary
Using a global proteomic approach to identify proteins affected by estrogen
therapy
Timothy D Veenstra
Address: Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-Frederick Inc., National Cancer
Institute at Frederick, Frederick, MD 21702, USA. Email: veenstra@ncifcrf.gov
Abstract
With the increase in technological capabilities for measuring biological molecules, there is a
greater trend to conduct non-biased, discovery-driven studies that collect information on
hundreds of molecules in a single study. The hope is that novel findings can be detected within
these large datasets. For protein analysis, these non-biased studies are particularly challenging as
no technology is presently capable of providing a view of the entire proteome. The ability of non-
biased studies to accurately detect specific differences within the proteomes of samples obtained
from differentially treated individuals must be conclusively demonstrated before investigators will
routinely adopt these methods as part of their experimental protocols. This need is especially
true for clinical and epidemiological studies in which limited amounts of samples are available.
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Conjugated equine estrogens (CEE) have been widely
administered for the relief of menopausal symptoms [1].
While there are obvious benefits to women suffering from
menopausal symptoms, estrogens are also known to exert
harmful effects. For instance, the evidence linking estrogen
metabolite levels and cancers of the reproductive system
continues to grow [2]. Scientists are also studying the effects
of estrogen metabolites in different racial populations. With
this information, physicians now are faced with wondering
which of their patients should have CEE administered. The
short-term benefits need to be carefully weighed against any
possible long-term detriments.
In 2003, the Women’s Health Initiative (WHI) reported that
women being administered CEE plus progesterone had an
increased number of cardiovascular events compared to
those given a placebo [3]. Unfortunately, confusion about
the benefits of hormone replacement therapy (HRT) was
introduced with the 2004 WHI estrogen-only trial that
showed no increase in such cardiovascular events. Although
this study did not provide a conclusive answer, it did suggest
that women aged 50 to 59 years who received estrogen
therapy enjoyed lower rates of heart disease [4]. A recent
study, entitled the WHI Coronary-Artery Calcium Study
(WHI-CACS), examined the effects of estrogen on coronary-
artery calcification in women between the ages of 50 and 59
who were enrolled in the CEE trial [5]. The results of this
study showed that women receiving estrogen had less
coronary-artery calcification compared to the control group
receiving a placebo.
Estrogen therapy is known to affect large numbers of
proteins and metabolites, beyond those related to cardio-
vascular events. Low- and high-density lipoproteins, tri-
glycerides, insulin, insulin-like growth factors, glucose and
C-reactive protein are just a few of the molecules whose
levels have been shown to be affected by estrogen adminis-
tration. Considering the wide range of effects that estrogen
exerts, there are undoubtedly many as yet undiscovered
molecules and functional pathways that are affected by
estrogen treatment. In the recent article published in
Genome Medicine entitled ‘Application of serum proteomics
to the Women’s Health Initiative conjugated estrogen equine
estrogens trial reveals a multitude of effects relevant to
clinical findings’, Katayama et al. [6] sought to discover
novel proteomic changes affected by CEE and also validate
the efficacy of using a global proteomic strategy for finding
these differences. This group used a method termed intact
protein analysis system (IPAS) to compare protein levels in
serum samples collected from women prior to initiation of
CEE treatment and one year after initiation of treatment.
Five separate analyses were conducted using samples
acquired from 50 women. The samples were prepared by
pooling equal-volume aliquots from groups of ten women.
The IPAS system utilizes two dimensions of chromatography
(anion exchange followed by reversed-phase) to fractionate
intact proteins. Aliquots collected from the reversed-phase
column are tryptically digested and the proteins are identi-
fied and quantified using high-throughput mass spectro-
metry (MS). Prior to their chromatographic separation, the
proteins from the CEE-treated and control group were
differentially isotopically labeled to allow their relative
abundances to be measured via the MS measurements. All of
the serum samples were also subjected to high-abundant
protein depletion, eliminating such proteins as albumin and
immunoglobulins from the analysis. The combination of
high-abundant protein removal and extensive fractionation
permitted proteins across seven orders of magnitude of
abundance to be measured.
A total of 611 proteins were quantified between the serum
samples acquired pre- and one-year post-CEE treatment. A
statistically significant difference in the abundance of 116
proteins was observed between the two comparative
samples. Of these, 64 proteins had a false discovery rate
(FDR) less than 0.5 relative to all of the quantified proteins.
Classification of these proteins into networks revealed five
significant functional processes that were affected by CEE
treatment: blood coagulation, kallikrein-kinin system, cell
adhesion-platelet-endothelium-leukocyte interactions, comple-
ment system, and ossification. Comparison of these 64
proteins to previous findings yielded 13 (>20%) that had
been reported in the literature to have an association with
estrogen therapy. The remaining 41 proteins where no
association with estrogen therapy had been previously
reported were associated with functions such as blood
coagulation, ossification, cell growth, blood pressure main-
tenance, blood vessel morphogenesis, and angiogenesis. To
confirm the IPAS results, enzyme-linked immunosorbent
assays (ELISAs) were carried out on 13 of the proteins using
both non-pooled samples that were part of the original IPAS
study and an independent sample set. In both validation
tests, the correlation between the results obtained from
these two methods was >0.83.
This manuscript provides an excellent demonstration of the
value of global comparative proteomic studies. Using a non-
biased method, Katayama et al. were able to correlate their
results with a number of findings that had previously been
reported to be associated with CEE. For example, CEE has
been associated with a reduction in hip fractures. The
authors were able to discover several proteins related to
ossification and osteogenesis that had increased abundances
in samples obtained from women that had been adminis-
tered CEE. They were also able to show changes in several
proteins that play roles in circulatory processes such as
coagulation, angiogenesis, and blood pressure regulation.
These results may be connected to the previously mentioned
benefits of lower heart disease rates.
There is a misconception related to the value of the infor-
mation to be gleaned from global proteomic studies as
illustrated by Katayama et al. Many scientists that are
unfamiliar with the technology anticipate that a global
comparison provides a ‘neat little package’ of proteins whose
abundance is affected by a particular stimulus. Unfortu-
nately, many investigators are exasperated when the data
they receive back is a long list of proteins with a large
number of them showing a change in abundance. Often
investigators find that the number of observed differences
overwhelms their ability to decide which direction to follow.
Katayama et al. have done an excellent job demonstrating
the efficacy of turning a list of proteins into meaningful
conclusions and further hypotheses. By grouping the
proteins that showed a significant change in abundance they
were able to uncover functional pathways that were affected
by CEE treatment. These findings can now be used to inter-
rogate specific proteins in order to gather a greater depth of
information concerning the effect of CEE on a physiological
function. In this study, a number of CEE-associated
functions were uncovered, some previously shown and some
novel. Following up on these non-biased results requires
selection of those functions that are most critical from a
public health view. This decision, while highly subjective,
needs to carefully consider the quality of the data obtained
in the global comparative study and the relative functional
importance of each protein pathway. For example, in the
search for a cancer biomarker, considerable effort would not
be exerted to further study acute phase response proteins,
although many of these would probably be detected as
having higher abundances in samples taken from cancer-
affected individuals.
What this study has illustrated is the utility of global
comparative proteomic analyses for identifying changes in
protein abundances within clinical samples obtained from
different groups of individuals. The affected proteins were
adequately validated using an orthogonal method and
independent sample set. While this study is not the first to
use a non-biased global approach to discover proteins and
molecules that change as a result of an external pertur-
bation, health scientists and institutions are still reluctant to
utilize technologies (such as the type used in this study) to
conduct investigative research. While such global proteomic
studies can be time consuming, taking months to complete,
the richness of information obtainable more than makes up
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for the effort spent. In this CEE study, five functional groups
of proteins were discovered to be perturbed, using the same
data set. This wealth of information provides large numbers
of hypotheses to be tested. Non-biased global studies, as
illustrated in this manuscript, are a very efficient route to
discovering novel effects of perturbations to biologic
systems.
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